Home Healthcare Biotechnology Antimicrobial Resistance Diagnostics Market

Antimicrobial Resistance Diagnostics Market Size, Share & Trends Analysis Report By Technology (Microbial Culture, Immunoassay, Polymerase Chain Reaction, Next-generation Sequencing, Mass Spectrometry, Others), By Pathogen (Methicillin-Resistant Staphylococcus Aureus, Drug-Resistant Streptococcus Pneumoniae, Drug-Resistant Campylobacter, Drug-Resistant Neisseria Gonorrhea, Drug-Resistant Salmonella, Others), By End Use (Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: January 13, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Antimicrobial Resistance Diagnostics Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. Microbial Culture
    2. Immunoassay
    3. Polymerase Chain Reaction
    4. Next-generation Sequencing
    5. Mass Spectrometry
    6. Others
  2. Antimicrobial Resistance Diagnostics Market, By Pathogen 2022-2034 (USD MILLION/ Units)
    1. Methicillin-Resistant Staphylococcus Aureus 
    2. Drug-Resistant Streptococcus Pneumoniae
    3. Drug-Resistant Campylobacter
    4. Drug-Resistant Neisseria Gonorrhea
    5. Drug-Resistant Salmonella
    6. Others
  3. Antimicrobial Resistance Diagnostics Market, By End Use 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Diagnostic Laboratories
    3. Pharmaceutical & Biotechnology Companies
    4. Others
  4. Regional Antimicrobial Resistance Diagnostics Market
    1. North America
      1. North America Antimicrobial Resistance Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
      2. North America Antimicrobial Resistance Diagnostics Market By Pathogen 2022-2034 (USD MILLION/ Units)
        1. Methicillin-Resistant Staphylococcus Aureus 
        2. Drug-Resistant Streptococcus Pneumoniae
        3. Drug-Resistant Campylobacter
        4. Drug-Resistant Neisseria Gonorrhea
        5. Drug-Resistant Salmonella
        6. Others
      3. North America Antimicrobial Resistance Diagnostics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic Laboratories
        3. Pharmaceutical & Biotechnology Companies
        4. Others
      4. U.S.
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      5. Canada
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
    2. Europe
      1. Europe Antimicrobial Resistance Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
      2. Europe Antimicrobial Resistance Diagnostics Market By Pathogen 2022-2034 (USD MILLION/ Units)
        1. Methicillin-Resistant Staphylococcus Aureus 
        2. Drug-Resistant Streptococcus Pneumoniae
        3. Drug-Resistant Campylobacter
        4. Drug-Resistant Neisseria Gonorrhea
        5. Drug-Resistant Salmonella
        6. Others
      3. Europe Antimicrobial Resistance Diagnostics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic Laboratories
        3. Pharmaceutical & Biotechnology Companies
        4. Others
      4. U.K.
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      5. Germany
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      6. France
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      7. Spain
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      8. Italy
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      9. Russia
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      10. Nordic
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      11. Benelux
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      12. Rest of Europe
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
    3. APAC
      1. APAC Antimicrobial Resistance Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
      2. APAC Antimicrobial Resistance Diagnostics Market By Pathogen 2022-2034 (USD MILLION/ Units)
        1. Methicillin-Resistant Staphylococcus Aureus 
        2. Drug-Resistant Streptococcus Pneumoniae
        3. Drug-Resistant Campylobacter
        4. Drug-Resistant Neisseria Gonorrhea
        5. Drug-Resistant Salmonella
        6. Others
      3. APAC Antimicrobial Resistance Diagnostics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic Laboratories
        3. Pharmaceutical & Biotechnology Companies
        4. Others
      4. China
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      5. Korea
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      6. Japan
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      7. India
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      8. Australia
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      9. Taiwan
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      10. South East Asia
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      11. Rest of Asia-Pacific
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
    4. Middle East and Africa
      1. Middle East and Africa Antimicrobial Resistance Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
      2. Middle East and Africa Antimicrobial Resistance Diagnostics Market By Pathogen 2022-2034 (USD MILLION/ Units)
        1. Methicillin-Resistant Staphylococcus Aureus 
        2. Drug-Resistant Streptococcus Pneumoniae
        3. Drug-Resistant Campylobacter
        4. Drug-Resistant Neisseria Gonorrhea
        5. Drug-Resistant Salmonella
        6. Others
      3. Middle East and Africa Antimicrobial Resistance Diagnostics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic Laboratories
        3. Pharmaceutical & Biotechnology Companies
        4. Others
      4. UAE
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      5. Turkey
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      6. Saudi Arabia
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      7. South Africa
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      8. Egypt
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      9. Nigeria
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      10. Rest of MEA
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
    5. LATAM
      1. LATAM Antimicrobial Resistance Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
      2. LATAM Antimicrobial Resistance Diagnostics Market By Pathogen 2022-2034 (USD MILLION/ Units)
        1. Methicillin-Resistant Staphylococcus Aureus 
        2. Drug-Resistant Streptococcus Pneumoniae
        3. Drug-Resistant Campylobacter
        4. Drug-Resistant Neisseria Gonorrhea
        5. Drug-Resistant Salmonella
        6. Others
      3. LATAM Antimicrobial Resistance Diagnostics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic Laboratories
        3. Pharmaceutical & Biotechnology Companies
        4. Others
      4. Brazil
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      5. Mexico
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      6. Argentina
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      7. Chile
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      8. Colombia
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
      9. Rest of LATAM
        1. Microbial Culture
        2. Immunoassay
        3. Polymerase Chain Reaction
        4. Next-generation Sequencing
        5. Mass Spectrometry
        6. Others
        7. Methicillin-Resistant Staphylococcus Aureus 
        8. Drug-Resistant Streptococcus Pneumoniae
        9. Drug-Resistant Campylobacter
        10. Drug-Resistant Neisseria Gonorrhea
        11. Drug-Resistant Salmonella
        12. Others
        13. Hospitals
        14. Diagnostic Laboratories
        15. Pharmaceutical & Biotechnology Companies
        16. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.